Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06203106
Other study ID # 10-010
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 10, 2022
Est. completion date November 10, 2045

Study information

Verified date March 2024
Source New York Stem Cell Foundation Research Institute
Contact Becca Wood
Phone 212-927-1801
Email clinicalresearch@nyscf.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.


Description:

Researchers at the New York Stem Cell Foundation (NYSCF) Research Institute study diverse diseases, conditions, and traits by creating stem cells from biological samples. These "pluripotent" stem cells can become any cell in the human body, including cells that may be difficult, invasive, or impossible to obtain directly. Additionally, researchers perform genetic testing to learn more about DNA, a material in most cells that contains instructions for the body's development and functions (such as traits like eye color and risk of certain diseases). A piece of DNA that determines the specific role of a cell is called a "gene." If the instructions in a gene are abnormal, this can lead to disease. Participation in the study involves: (1) completion of health questionnaires, (2) providing a skin and/or blood sample from which stem cells may be created, (3) collection of a saliva sample for genetic analysis, and (4) possible future followup to provide additional information or learn about other research studies. This study is not a clinical trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 10000
Est. completion date November 10, 2045
Est. primary completion date November 10, 2045
Accepts healthy volunteers
Gender All
Age group 30 Days and older
Eligibility Inclusion Criteria: - Age 30 days or older. - Diagnosis and/or medical history of a condition, disease, genetic background, or trait of interest or healthy control. - Adults with decisional capacity must provide written informed consent unless physical limitations preclude signing. - Adults without decisional capacity to consent must a have diagnosis of Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease and Related Dementias (AD/ADRD); Batten Disease, Corticobasal Degeneration (CBD), Dementia, Frontotemporal Dementia (FTD), Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson's Disease (PD), Parkinsonism, and/or Progressive Supranuclear Palsy, and must provide assent; a legally authorized representative (LAR) must also provide written informed consent. - Minors undergoing skin collection for research purposes must have a condition, disease, genetic background, or trait of interest and parental/guardian consent. - Minors undergoing blood, and/or saliva collection for research purposes may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent. - Minors transferring biological samples and associated data from a procedure outside of the research may have a condition, disease, genetic background, or trait of interest or serve as a healthy control and must have an available parent/guardian to provide consent. Exclusion Criteria: - Wards of the state. - For prospective skin samples: history of keloid formation, coagulation disorder, or allergy to the anesthetic. - For prospective blood samples: history of coagulation disorder. - For all prospective sample collections: 1) Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocol(s) will be excluded; 2) Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.

Study Design


Related Conditions & MeSH terms

  • ALS
  • Alzheimer Disease
  • Alzheimer Disease, Early Onset
  • Alzheimer Disease, Late Onset
  • Amyotrophic Lateral Sclerosis
  • Aphasia, Primary Progressive
  • Atrophy
  • Batten Disease
  • Cervical Cancer
  • Corticobasal Degeneration
  • Dementia
  • Diabetes
  • Diabetes Mellitus
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Frontotemporal Dementia
  • Huntington Disease
  • INAD
  • Lewy Body Disease
  • Macular Degeneration
  • Motor Neuron Disease
  • Multiple Sclerosis
  • Multiple System Atrophy
  • Neuronal Ceroid-Lipofuscinoses
  • Ovarian Cancer
  • Ovarian Neoplasms
  • Parkinson Disease
  • Parkinson's Disease and Parkinsonism
  • Parkinsonian Disorders
  • Pick Disease of the Brain
  • Post Traumatic Stress Disorder
  • Progressive Supranuclear Palsy
  • PTSD
  • Sclerosis
  • Shy-Drager Syndrome
  • Stress Disorders, Post-Traumatic
  • Stress Disorders, Traumatic
  • Supranuclear Palsy, Progressive
  • Uterine Cancer
  • Uterine Cervical Neoplasms
  • Uterine Neoplasms
  • Vaginal Cancer
  • Vaginal Neoplasms
  • Vulvar Cancer
  • Vulvar Neoplasms

Intervention

Other:
Biological Sample Collection
Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/ leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure).

Locations

Country Name City State
United States New York Stem Cell Foundation Research Institute New York New York

Sponsors (1)

Lead Sponsor Collaborator
New York Stem Cell Foundation Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Biobank Establishment of a diverse repository of biological samples, stem cell lines, derivatives, and associated information to support investigations into the biology, etiology, manifestations, progression, risk factors, genetic underpinnings, and treatment of diseases, conditions, and traits. Baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2